428 related articles for article (PubMed ID: 29128105)
21. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
Horner W; Peng K; Pleasant V; Brackmann M; Ebott J; Gutfreund R; McLean K; Reynolds RK; Uppal S
Gynecol Oncol; 2019 Aug; 154(2):283-289. PubMed ID: 31196575
[TBL] [Abstract][Full Text] [Related]
22. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
23. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.
Yang SP; Chen JX; Xu JY; Lei J; Wu SG; Zhou J
Cancer Med; 2022 Jul; 11(14):2836-2845. PubMed ID: 35274489
[TBL] [Abstract][Full Text] [Related]
24. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
25. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
26. A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
Eoh KJ; Yoon JW; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
BMC Cancer; 2017 Jul; 17(1):481. PubMed ID: 28701190
[TBL] [Abstract][Full Text] [Related]
27. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
28. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
Meyer LA; Cronin AM; Sun CC; Bixel K; Bookman MA; Cristea MC; Griggs JJ; Levenback CF; Burger RA; Mantia-Smaldone G; Matulonis UA; Niland JC; O'Malley DM; Wright AA
J Clin Oncol; 2016 Nov; 34(32):3854-3863. PubMed ID: 27601552
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591
[TBL] [Abstract][Full Text] [Related]
31. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
33. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
Qin L; Huang H; Chen M; Liang Y; Wang H
J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Bogani G; Matteucci L; Tamberi S; Arcangeli V; Ditto A; Maltese G; Signorelli M; Martinelli F; Chiappa V; Leone Roberti Maggiore U; Perotto S; Scaffa C; Comerci G; Stefanetti M; Raspagliesi F; Lorusso D
Int J Gynecol Cancer; 2017 Nov; 27(9):1856-1862. PubMed ID: 29064913
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
36. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
[TBL] [Abstract][Full Text] [Related]
37. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
38. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
[TBL] [Abstract][Full Text] [Related]
39. Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
Weaver DT; Raphel TJ; Melamed A; Rauh-Hain JA; Schorge JO; Knudsen AB; Pandharipande PV
Gynecol Oncol; 2018 May; 149(2):256-262. PubMed ID: 29486993
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
Gynecol Oncol; 2016 Oct; 143(1):3-15. PubMed ID: 27650684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
